Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer

Cetuximab is approved for the treatment of metastatic colorectal cancer (mCRC) with RAS wild-type. Nevertheless, the prognosis remains poor and the effectiveness of cetuximab is limited in KRAS mutant mCRC. Recently, emerging evidence has shown that ferroptosis, a newly discovered form of nonapoptot...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jiawen, Mo, Jiajie, Dai, Juji, Ye, Chenqiao, Cen, Wei, Zheng, Xuzhi, Jiang, Lei, Ye, Lechi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590697/
https://www.ncbi.nlm.nih.gov/pubmed/34775496
http://dx.doi.org/10.1038/s41419-021-04367-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590697/
https://www.ncbi.nlm.nih.gov/pubmed/34775496
http://dx.doi.org/10.1038/s41419-021-04367-3

Ejemplares similares